18F-αvβ6-BP for Cancer

Age: 18+

Sex: Any

Trial Phase: Phase < 1

Sponsor: Julie L. Sutcliffe, Ph.D

Disqualifiers: Pregnancy, Breast-feeding, Life expectancy < 3 mo, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: 1

Duration: 1 day

27 Participants Needed

Trial Summary

What is the purpose of this trial?

This clinical trial studies the side effects of 18F-alphavbeta6-binding-peptide and how well it works in imaging patients with primary or cancer that has spread to the breast, colorectal, lung, or pancreatic. Radiotracers, such as 18F-alphavbeta6-binding-peptide, may improve the ability to locate cancer in the body.

Research Team

Julie Sutcliffe

Principal Investigator

University of California, Davis

Eligibility Criteria

This trial is for people with primary or metastatic breast, colorectal, lung, or pancreatic cancer who can stay still for PET scans and have a good performance status. It's not for those with severe kidney/liver issues, very short life expectancy, pregnant/breastfeeding women, recent investigational drug use, or inability to undergo PET/CT scans.

Inclusion Criteria

I am fully active or have some restrictions but can still care for myself.

I can stay still for up to an hour.

My cancer is in the breast, colorectal, lung, or pancreas.

Exclusion Criteria

Lack of availability for follow-up assessments

I am currently pregnant or breastfeeding.

You are unable to have a PET/CT scan.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive 18F-alphavbeta6-BP intravenously and undergo 4 PET scans over 30 minutes each at 30, 60, 120, and 180 minutes post-injection

1 day

1 visit (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

6 months

Treatment Details

Interventions

• 18F-αvβ6-BP

Trial Overview The study tests the safety and imaging effectiveness of a radiotracer called 18F-αvβ6-binding-peptide in detecting cancers such as breast, colorectal, lung and pancreatic when used during PET scans.

Participant Groups

Group I: 18F-αvβ6-BP Experimental Treatment 1 Intervention

Patients receive 18F-alphavbeta6-BP IV and then undergo 4 PET scans over 30 minutes each at 30, 60, 120, and 180 minutes post-injection.

Who Is Running the Clinical Trial?

Julie L. Sutcliffe, Ph.D

Lead Sponsor

Trials

1

Recruited

30+

National Cancer Institute (NCI)

Collaborator

Trials

14,080

Recruited

41,180,000+